• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过 COVID-19 疫苗研发投资确保可及性和可负担性：疫苗期权市场的建议。

Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.

机构信息

London School of Economics and Political Science, London, UK.

London School of Economics and Political Science, London, UK.

出版信息

Vaccine. 2020 Sep 3;38(39):6075-6077. doi: 10.1016/j.vaccine.2020.07.068. Epub 2020 Jul 31.

DOI:10.1016/j.vaccine.2020.07.068
PMID:32773244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7834564/
Abstract

• Currently, unconditional investment is being made into COVID-19 vaccine R&D COVID-19 vaccine R&D investments should also ensure access and affordability. • The options market for antibiotics, could be adapted for use with COVID-19 vaccines. • This could help fund R&D, boost manufacturing capacity and secure fair prices. • Further research on the OMV model in the current COVID-19 crisis is warranted.

摘要

• 目前，正在对 COVID-19 疫苗研发进行无条件投资，COVID-19 疫苗研发投资还应确保可及性和可负担性。• 可以对用于抗生素的期权市场进行调整，以用于 COVID-19 疫苗。• 这有助于为研发提供资金，提高生产能力并确保公平价格。• 在当前 COVID-19 危机中有必要进一步研究 OMV 模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75d8/7834564/8793a13851b9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75d8/7834564/8793a13851b9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75d8/7834564/8793a13851b9/gr1_lrg.jpg

相似文献

1
Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.通过 COVID-19 疫苗研发投资确保可及性和可负担性：疫苗期权市场的建议。
Vaccine. 2020 Sep 3;38(39):6075-6077. doi: 10.1016/j.vaccine.2020.07.068. Epub 2020 Jul 31.
2
Keeping track of the SARS-CoV-2 vaccine pipeline. 跟踪 SARS-CoV-2 疫苗研发管线。
Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1.
3
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Jun 3;16(696):1176-1177.
4
Coronavirus vaccines get a biotech boost.冠状病毒疫苗获得生物技术助力。
Nature. 2020 Jul;583(7817):647-649. doi: 10.1038/d41586-020-02154-2.
5
Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.探索新冠疫苗加速反应中的不确定性和风险：来自制药行业的观点。
Vaccine. 2020 Nov 10;38(48):7588-7595. doi: 10.1016/j.vaccine.2020.10.034. Epub 2020 Oct 13.
6
If a coronavirus vaccine arrives, can the world make enough?如果新冠病毒疫苗问世，全球能够生产出足够的量吗？
Nature. 2020 Apr;580(7805):578-580. doi: 10.1038/d41586-020-01063-8.
7
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.布莱顿协作组织（ Brighton Collaboration ）用于收集灭活病毒疫苗的获益-风险评估关键信息的标准化模板。
Vaccine. 2020 Sep 3;38(39):6184-6189. doi: 10.1016/j.vaccine.2020.07.028. Epub 2020 Jul 31.
8
COVID-19 vaccine trials: Duty of care and standard of prevention considerations.2019冠状病毒病疫苗试验：注意义务与预防标准考量
Vaccine. 2020 Nov 10;38(48):7578-7580. doi: 10.1016/j.vaccine.2020.10.012. Epub 2020 Oct 9.
9
Global governance for COVID-19 vaccines.新冠疫苗的全球治理
Lancet. 2020 Jun 20;395(10241):1883. doi: 10.1016/S0140-6736(20)31405-7.
10
COVID-19 vaccines for all?全民接种新冠疫苗？
Lancet. 2020 Jun 13;395(10240):1822-1823. doi: 10.1016/S0140-6736(20)31354-4.

引用本文的文献

1
Funding Sources of Therapeutic and Vaccine Clinical Trials for COVID-19 vs Non-COVID-19 Indications, 2020-2021.COVID-19 与非 COVID-19 适应证治疗和疫苗临床试验的资金来源，2020-2021 年。
JAMA Netw Open. 2022 Aug 1;5(8):e2226892. doi: 10.1001/jamanetworkopen.2022.26892.
2
Barriers to COVID-19 Health Products in Low-and Middle-Income Countries During the COVID-19 Pandemic: A Rapid Systematic Review and Evidence Synthesis.新冠肺炎大流行期间中低收入国家的 COVID-19 卫生产品障碍：快速系统评价和证据综合。
Front Public Health. 2022 Jul 22;10:928065. doi: 10.3389/fpubh.2022.928065. eCollection 2022.
3
COVID-19: The Pseudo-Environment and the Need for a Paradigm Change.

本文引用的文献

1
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的安全性和免疫原性：一项 1/2 期、单盲、随机对照临床试验的初步报告。
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
2
Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.体系，而非药丸：抗生素期权市场力求振兴抗生素研发渠道。
Soc Sci Med. 2016 Feb;151:167-72. doi: 10.1016/j.socscimed.2016.01.005. Epub 2016 Jan 14.
3
新冠病毒肺炎：拟态环境与范式转变的必要性
Germs. 2021 Dec 29;11(4):468-477. doi: 10.18683/germs.2021.1283. eCollection 2021 Dec.
4
Drawing light from the pandemic: Rethinking strategies for health policy and beyond.从疫情中汲取经验：重新思考卫生政策及其他领域的策略。
Health Policy. 2022 Jan;126(1):1-6. doi: 10.1016/j.healthpol.2021.12.001. Epub 2021 Dec 5.
5
COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance.新冠疫苗接种：挑战的根源与谏言的种子
Vaccines (Basel). 2021 Dec 13;9(12):1474. doi: 10.3390/vaccines9121474.
6
Navigating the role of the EU Health Emergency Preparedness and Response Authority (HERA) in Europe and beyond.厘清欧盟卫生应急准备与响应局（HERA）在欧洲及其他地区所扮演的角色。
Lancet Reg Health Eur. 2021 Oct;9:100203. doi: 10.1016/j.lanepe.2021.100203. Epub 2021 Oct 7.
7
The Relationship Between the COVID-19 Pandemic and Vaccine Hesitancy: A Scoping Review of Literature Until August 2021.《2021 年 8 月前 COVID-19 大流行与疫苗犹豫的关系：文献范围综述》。
Front Public Health. 2021 Sep 28;9:747787. doi: 10.3389/fpubh.2021.747787. eCollection 2021.
8
Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.全球获取 COVID-19 疫苗：可能影响中低收入国家公平获取疫苗的因素的范围综述。
BMJ Open. 2021 Sep 30;11(9):e049505. doi: 10.1136/bmjopen-2021-049505.
9
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?COVID-19 疫苗面临的挑战：到目前为止我们了解到了什么，还有什么需要做？
Health Policy. 2021 May;125(5):553-567. doi: 10.1016/j.healthpol.2021.03.013. Epub 2021 Mar 26.
10
Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China.普通民众在 COVID-19 大流行早期阶段对 COVID-19 疫苗接种的接受意愿和付费意愿：中国大陆一项全国代表性调查。
Hum Vaccin Immunother. 2021 Jun 3;17(6):1622-1627. doi: 10.1080/21645515.2020.1847585. Epub 2021 Feb 19.
Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
新抗生素的激励措施：抗生素期权市场（OMA）模型。
Global Health. 2013 Nov 7;9:58. doi: 10.1186/1744-8603-9-58.
4
Risk in vaccine research and development quantified.疫苗研发风险量化。
PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20.